Spectral Medical Inc. (TSX:EDT)

Market Cap	404.92M +75.3%
Revenue (ttm)	2.76M +26.1%
Net Income	-38.03M
EPS	-0.14
Shares Out	293.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,862
Average Volume	60,286
Open	1.380
Previous Close	1.380
Day's Range	1.370 - 1.420
52-Week Range	0.770 - 1.840
Beta	0.17
RSI	51.89
Earnings Date	Aug 12, 2026

About Spectral Medical

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, an...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1991
• Employees: 29
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: EDT

Financial Performance

In 2025, Spectral Medical's revenue was 2.44 million, an increase of 6.82% compared to the previous year's 2.29 million. Losses were -47.69 million, 209.6% more than in 2024.